Affimed raises €20 million in Series C round

Affimed Therapeutics AG of Germany has raised €20 million in a Series C round to bring it antibody candidate for Hodgkin’s lymphoma into the clinic and develop its pipeline. The round was led by existing investors including Novo Nordisk A/S.